尽管收入丰厚,分析家前景看好,但内部人出售股票。 Insiders sold shares despite strong earnings and positive analyst outlook.

2026年1月2日,Janux Therapeutics内部人士大卫·艾伦·坎贝尔和扎卡里亚·麦西弗出售了股票,坎贝尔将他的股份减少了2.75%,而麦西弗则减少了10.44%,两者均为每股13.73美元. On January 2, 2026, Janux Therapeutics insiders David Alan Campbell and Zachariah Mciver sold shares, with Campbell reducing his stake by 2.75% and Mciver by 10.44%, both at $13.73 per share. 库存以13.65美元关闭,减少了15美元,交易额低于平均交易额。 The stock closed at $13.65, down $0.15, with below-average trading volume. 该公司报告了强劲的2025年Q3结果,每股损失0.39美元,高于预期,收入1 000万美元,远远超过预测。 The company reported strong Q3 2025 results, posting a $0.39 loss per share—better than expected—and $10 million in revenue, far exceeding forecasts. 分析员预期本财政年度将损失1.38美元,以协商一致的“机动购买”评级和61.08美元的目标价格。 Analysts expect a $1.38 loss for the current fiscal year, with a consensus "Moderate Buy" rating and a $61.08 target price. 该公司的重点是宫内免疫-肿瘤治疗,市场上限为8.21亿美元,机构所有权为75.39%。 The company, focused on intratumoral immuno-oncology therapies, has a market cap of $821 million and 75.39% institutional ownership.